Industry News

CytRx Corporation securities between November 18, 2014 and July 11, 2016, inclusive. CytRx investors have until September 23, 2016 to file a lead plaintiff motion. Investors suffering losses on their CytRx investments are encouraged to contact Casey Sadler of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of CytRx Corporation Investors and Encourages Investors to Contact the Firm
American Renal Associates Holdings, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws. American Renal provides kidney dialysis services to patients across the country. According to recent news reports, and a complaint filed by UnitedHealth Group, Inc., the Company has allegedly steered patients away from Medicare and Medicaid programs into..."/>
Glancy Prongay & Murray LLP Commences Investigation on Behalf of American Renal Associates Holdings, Inc. Investors
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, is pleased to announce that company management will present at the following investor conferences in September:. 2016 Wells Fargo Healthcare Conference. Date: Wednesday, September 7, 2016."/>
Cambrex to Present at Upcoming Investor Conferences in September
Lupin Ltd, the country's Mumbai-based third largest drug maker, said on Friday that it had received tentative approval from the United States Food and Drug Administration for its Paroxetine Extended-Release Tablets USP, 12.5 mg, 25 mg and 37.5 mg. Lupin can now potentially market a generic version of Canada-based Apotex Technologies Inc.' s anti-depressant tablet Paxil CR tablets of the same dosage. When the patents or exclusivities granted to a brand-name..."/>
Lupin secures tentative FDA nod for anti-depressant drug Paxil [Mint, New Delhi]
Invacare Corporation announced that it declared a cash dividend of$. 0125 per share on its common shares and$. 011364 per share on its Class B common shares payable October 21, 2016 to shareholders of record on October 13, 2016.. Invacare Corporation, headquartered in Elyria, Ohio, is a global leader in the manufacture and distribution of innovative home and long-term care medical products that promote recovery and active lifestyles."/>
Invacare Declares Quarterly Dividend
Mettrum Health Corp.,, a vertically integrated provider of cannabis products, is pleased to announce that it has completed its previously announced bought deal offering of 5,661,000 common shares of the Company, at a price of $2.65 per Share for aggregate gross proceeds of $15,001,650."/>
Mettrum Health Corp. Closes $15 Million Bought Deal Offering of Common Shares
Cambrex Corporation, the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients, is pleased to announce that company management will present at the following investor conferences in September:. The live audio webcasts and slide presentations can be accessed from the Cambrex website at www.cambrex.com in the Investors section under“ Webcasts& Presentations”, and replays will be available for 90 days..."/>
Cambrex to Present at Upcoming Investor Conferences in September
Facebook data center in far north Fort Worth. In an interview, Berzina said he was pursuing another job but declined to provide specifics "until it is sewed up.""/>
Fort Worth Chamber's top economic development exec steps down [Fort Worth Star-Telegram]
HealthEquity, Inc., a nationwide health savings account administrator, hosted an open house for the opening of its new building in Draper, Utah. HealthEquity employs 662 Utah-based professionals with 160 team members moving to the new building with room for continued growth. The new building is located at 38 E. Scenic Pointe Drive."/>
Utah Gov. Gary Herbert Celebrates Opening of HealthEquity's Second Building in Utah
Daily Mail, London, market report column [Daily Mail, London]
OPKO Health, Inc., announces that at a Special Shareholder Meeting held on August 25, 2016 shareholders of Transition Therapeutics, Inc. holding approximately 93% of the outstanding common shares, voted to approve the previously announced agreement under which OPKO Health will acquire Transition Therapeutics. The acquisition is subject to final approval of the Ontario Superior Court Justice. The Court hearing for the final order is scheduled to take place on August..."/>
Transition Therapeutics Shareholders Approve Acquisition by OPKO Health
Spotlight Innovation Inc. has entered into a Sponsored Research Agreement with Florida State University to support research directed by FSU Prof. Hengli Tang aimed at developing safe and effective drugs to treat patients infected with Zika virus. Tang is an accomplished virologist whose research has been published in prominent academic journals including Cell and Journal of Virology."/>
Spotlight Innovation Enters into Sponsored Research Agreement with Florida State University to Support Prof. Hengli Tang in the Development of Treatments for Zika Virus Infection
Response Biomedical Corp.– Further to TSX Bulletin 2016-0682 dated July 4, 2016, TSX has decided to extend its review of the eligibility of the common shares of the Company for continued listing for a period of 30 days. About TMX Group TMX Group's key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities, fixed income and energy. Toronto Stock Exchange, TSX Venture Exchange,..."/>
TSX Delisting Review - Response Biomedical Corp. (Symbol: RBM)
PositiveID Corporation, a life sciences company focused on detection and diagnostics, announced today that it has completed its acquisition of Thermomedics Inc., the designer and marketer of the Caregiver ® infrared, non-contact thermometer, which is FDA-cleared for clinical use. Under a management services and control agreement, PositiveID assumed full operational control of Thermomedics in December 2015. PositiveID has now completed the..."/>
PositiveID Completes Acquisition of Thermomedics and the Caregiver Non-Contact Thermometer
Limbach Holdings, the 115- year-old Strip District-based contractor that survived four years of ownership by bankrupt energy giant Enron, is ready to expand services and enter new markets following an initial public offering last month. CEO Charlie Bacon, 55, said the two biggest growth priorities are offering electrical expertise in more markets to complement Limbach's mechanical and plumbing services, and entering Texas, the Carolinas, Seattle and other markets..."/>
Contractor Limbach charts growth after IPO [Pittsburgh Post-Gazette]
Portola Pharmaceuticals Inc. ® today announced that interim results from its ongoing Phase 3 b/4 ANNEXA™ -4 trial of AndexXa™, a Factor Xa inhibitor antidote, will be featured in an oral Late-Breaking Science Hot Line session at the European Society of Cardiology 2016 Congress, which will take place from August 27– 31 in Rome. The data also will be featured in the ESC’ s Hot Line– Preventive Strategies II press conference on Tuesday, August 30, at..."/>
Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress
TG Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has granted orphan drug designation for TG-1101 the Company’ s novel, glycoengineered anti-CD20 monoclonal antibody, for the treatment of patients with neuromyelitis optica and neuromyelitis optica spectrum disorder. There are currently no FDA approved treatments for NMO or NMOSD.."/>
TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
Syros Pharmaceuticals announced today that its Chief Executive Officer Nancy Simonian, M.D., will present a corporate overview at BioCentury’ s 23 rd Annual NewsMakers in the Biotech Industry Conference. BioCentury’ s 23 rd Annual NewsMakers in the Biotech Industry Conference Date: Friday, September 9 Time: 2-2: 25 p.m. Location: Millennium Broadway Hotel, 145 West 44 th Street, New York, NY. A live webcast of the presentation will be available on the News& Investors..."/>
Syros Pharmaceuticals to Present at BioCentury NewsMakers Conference
MediWound Ltd., a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, announces that Company management will participate at the 11 th Annual Wells Fargo Securities Healthcare Conference taking place from September 7-8, 2016 in Boston. Gal Cohen, President and Chief Executive Officer, will deliver MediWound’ s presentation on Wednesday, September 7th at 9:20 a.m...."/>
MediWound to Present at 11th Annual Wells Fargo Healthcare Conference
Progenics Pharmaceuticals Inc., Peregrine Pharmaceuticals Inc., Agios Pharmaceuticals Inc., and Cara Therapeutics Inc.. On Wednesday, August 24, 2016, the iShares NASDAQ Biotechnology ETF plummeted 3% after Democratic presidential candidate Hillary Clinton tweeted about the price hikes on EpiPens."/>
How These Biotech Stocks are Faring? -- Progenics Pharma, Peregrine Pharma, Agios Pharma, and Cara Therapeutics
Uni-Bio Science Group Limited has announced its interim results for the six months ended 30 June 2016. The Group achieved strong financial and operational performance as a result of well-managed tenders by the new Market Access department, strengthening its commercial platform, and successful penetration of new growth provinces. Highlights:- Normalized sales grew 25.6%, significantly beating industry growth of 9.0%- Normalized net loss narrowed by..."/>
Uni-Bio Science Group Announces 2016 Interim Results
Walgreens Boots Alliance said on Thursday that it has agreed to amend the second tranche of warrants with AmerisourceBergen. Walgreens Boots Alliance will now purchase AmerisourceBergen's common stock so as to permit the immediate exercise of these warrants. The company added that the warrants were originally scheduled to be exercisable in March 2017.."/>
Walgreens Boots Alliance announces exercise of second tranche of warrants from AmerisourceBergen Shares
NeuroDerm said on Thursday that it has started enrollment of patients with Parkinson's disease under its Phase III efficacy trial of its low-dose continuous, subcutaneously delivered levodopa/carbidopa liquid formulation ND0612L. The company added that iNDiGO is a 16- week, international, multicentre, randomised, double-blind, placebo controlled, parallel group study designed to compare the efficacy, safety and tolerability of continuous..."/>
NeuroDerm initiaties iNDiGO trial of ND0612L in Parkinson’s Disease patients

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary726 Articles
Information Technology683 Articles
Financials563 Articles
Health Care406 Articles
Industrials397 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.